Glooko宣布收购Monarch Medical Technologies，以扩展其联网糖尿病护理产品-动脉网

Glooko Announces Acquisition of Monarch Medical Technologies, Maker of EndoTool Glucose Management System, to Expand Connected Diabetes Care Offerings

Healthcare IT Today 等信源发布 2025-10-28 21:12



可切换为仅中文







Acquisition Extends Glooko’s Diabetes Digital Health Platform into Hospitals, Creating a Comprehensive Inpatient-to-Outpatient Diabetes Management Connected Care Solution

收购使Glooko的糖尿病数字健康平台扩展到医院，创建了一个全面的住院到门诊糖尿病管理连接护理解决方案。

Deal Underscores Glooko’s Commitment to Accelerating Growth and Innovation in Diabetes Care

交易凸显了Glooko致力于加速糖尿病护理领域的增长和创新的承诺。

Glooko, Inc.

Glooko公司

, a leading provider of remote patient monitoring and digital health solutions for diabetes, today announced that it has acquired

，一家为糖尿病提供远程患者监测和数字健康解决方案的领先提供商，今天宣布已完成收购

Monarch Medical Technologies

君主医疗技术公司

, the developer of the EndoTool Glucose Management System. EndoTool is an industry-leading software platform for inpatient insulin dosing and glycemic management. This strategic acquisition expands Glooko’s connected care capabilities into inpatient glycemic management, complementing its strong foundation in outpatient diabetes management and shaping the future of a single, integrated solution that will support patients and clinicians across the full continuum of care..

，EndoTool葡萄糖管理系统的开发者。EndoTool是一个行业领先的软件平台，用于住院胰岛素剂量和血糖管理。此次战略性收购扩展了Glooko在住院血糖管理方面的连接护理能力，补充了其在门诊糖尿病管理方面的坚实基础，并塑造了一个单一的、集成的解决方案的未来，该方案将支持整个护理过程中的患者和临床医生。

“This acquisition represents a pivotal step in Glooko’s mission to transform diabetes management in every care setting,” said Mike Alvarez, Chief Executive Officer at Glooko. “We’ve built a strong foundation in the outpatient space — simplifying diabetes management for clinicians through unified device integration, EHR connectivity, and actionable insights.

“这次收购标志着Glooko在实现其转变各护理环境下糖尿病管理任务的关键一步，”Glooko首席执行官Mike Alvarez表示。“我们在门诊领域已经建立了坚实的基础——通过统一的设备集成、电子健康记录连接和可操作的见解简化了临床医生的糖尿病管理。”

By adding Monarch’s proven inpatient insulin dosing expertise, we’re now uniquely positioned to deliver a truly comprehensive hospital-to-home solution that can improve outcomes, streamline workflows, and enhance patient safety. Looking ahead, this platform also creates opportunities to extend our leadership into primary care and advanced glycemic management, enabling us to serve patients and providers across the full continuum of care.”.

通过加入Monarch经过验证的住院胰岛素剂量专业知识，我们现在能够提供一个真正全面的从医院到家庭的解决方案，该方案可以改善结果、简化工作流程并提高患者安全。展望未来，这个平台还为我们扩展在初级护理和高级血糖管理领域的领导地位创造了机会，使我们能够在整个护理过程中为患者和医疗服务提供者提供服务。

Inpatient glycemic management is vital to patient safety, outcomes, and hospital performance, with 30–40% of hospitalized patients requiring insulin therapy to maintain acceptable glucose control. Poor glucose management can lead to serious complications, longer stays, and higher costs. EndoTool, an FDA-cleared software platform that assists clinicians in optimizing insulin dosing for hospitalized patients, uses a patented, patient-specific algorithm to deliver precise, guideline-aligned insulin dosing in real time, reducing the risk of hypoglycemia and helping hospitals meet CMS quality measures while streamlining clinical workflows..

住院患者的血糖管理对于患者安全、治疗效果和医院绩效至关重要，30%-40%的住院患者需要胰岛素治疗以维持可接受的血糖控制。血糖管理不当可能导致严重并发症、住院时间延长和成本增加。EndoTool是一款获得FDA批准的软件平台，协助临床医生优化住院患者的胰岛素剂量，其使用一种获得专利的、针对患者特定情况的算法，实时提供精确且符合指南的胰岛素剂量建议，降低低血糖风险，帮助医院满足CMS质量指标，同时简化临床工作流程。

“Effective glycemic management doesn’t begin or end at the hospital doors. It’s a continuous journey,” said Mark Clements, M.D., Ph.D., Chief Medical and Strategy Officer at Glooko. “With new CMS quality measures and HEDIS metrics driving the need for consistent glucose control, connected solutions are no longer optional; they’re essential.

“有效的血糖管理并非始于或终于医院的大门。这是一个持续的过程，”Glooko首席医疗与战略官马克·克莱门茨（Mark Clements）博士表示。“随着新的CMS质量指标和HEDIS标准推动对持续血糖控制的需求，互联解决方案已不再是可选项，而是必不可少的。”

By integrating EndoTool with Glooko’s outpatient platform, we believe we will be better able to ensure safer care transitions for people with diabetes, help hospitals meet quality and regulatory requirements, and deliver measurable improvements in patient outcomes across the continuum.”.

通过将EndoTool与Glooko的门诊平台整合，我们相信将能够更好地确保糖尿病患者的安全护理过渡，帮助医院满足质量和监管要求，并在整个护理过程中为患者带来可衡量的改善。

The acquisition of Monarch Medical advances Glooko’s strategic focus on connected care in diabetes management. Glooko’s platform, used by millions of patients and more than 8,000 clinics worldwide, aggregates data from more than 200 connected devices – including blood glucose meters, insulin pumps, continuous glucose monitors (CGMs), and others – to make diabetes management easier for endocrinologists, primary care providers, nurses, diabetes educators, dietitians, and other clinicians by unifying data from a variety of devices onto a single platform, integrating smoothly with EHR workflows, and delivering actionable insights.

收购Monarch Medical推进了Glooko在糖尿病管理中对互联护理的战略重点。Glooko的平台被全球数百万患者和8000多家诊所使用，汇集了200多个连接设备的数据——包括血糖仪、胰岛素泵、连续血糖监测仪（CGMs）等——通过将来自各种设备的数据整合到一个平台上，与电子健康记录（EHR）工作流程无缝集成，并提供可操作的见解，从而让内分泌科医生、初级保健提供者、护士、糖尿病教育者、营养师及其他临床医生更轻松地管理糖尿病。

By adding EndoTool to its platform, Glooko will support acute care settings with precision insulin dosing algorithms and continue to support those patients post-discharge via its remote monitoring tools. This integrated approach aims to reduce hospital readmissions, enhance continuity of care, and improve overall glycemic control across settings..

通过将EndoTool添加到其平台，Glooko将通过精确的胰岛素剂量算法为急性护理环境提供支持，并通过其远程监控工具继续在患者出院后提供支持。这种集成方法旨在减少医院再入院率，增强护理的连续性，并改善跨环境的整体血糖控制。

The combined company will maintain all current offerings and support for both Glooko and EndoTool customers. In the near term, Glooko and Monarch Medical will continue to operate their products as they do today, ensuring no disruption for users. Longterm, Glooko plans to integrate both offerings on a single platform..

合并后的公司将保留对Glooko和EndoTool客户的所有当前产品和服务支持。短期内，Glooko和Monarch Medical将继续按照现有方式运营其产品，确保用户不受影响。长期来看，Glooko计划将两者整合到一个平台上。

Building on Strong Investor Backing

建立在强大的投资者支持基础上

This acquisition follows Glooko’s $100 million Series F financing round completed in October 2024, led by Georgian with participation from Canaan Partners, Health Catalyst Capital, Mayo Ventures, Realization Capital Partners, and other strategic investors. At that time, Glooko outlined its intent to accelerate growth through both product innovation and selective acquisitions.

此次收购是在Glooko于2024年10月完成的1亿美元F轮融资之后进行的，该轮融资由Georgian领投，Canaan Partners、Health Catalyst Capital、Mayo Ventures、Realization Capital Partners以及其他战略投资者参与。当时，Glooko表示计划通过产品创新和选择性收购来加速增长。

The addition of Monarch Medical demonstrates how that capital and investor support are fueling Glooko’s strategy to expand its connected care platform, extend its reach into new care settings, and solidify its position as a global leader in digital health for diabetes management..

Monarch Medical 的加入表明，资本和投资者的支持正在推动 Glooko 扩展其互联护理平台的战略，将其覆盖范围延伸至新的护理场景，并巩固其在糖尿病管理数字健康领域的全球领先地位。

Terms of the acquisition are not being disclosed.

收购条款未被披露。

About Glooko

关于Glooko

Glooko is focused on improving health outcomes for people with diabetes through our personalized, intelligent, connected care platform. Our proven technologies strengthen connections between patients and providers, drive patient engagement and adherence via digital therapeutics, with more than 4.4 million people around the world who have used the Glooko platform.

Glooko致力于通过我们个性化、智能、互联的护理平台，改善糖尿病患者的健康状况。我们经过验证的技术加强了患者与医疗服务提供者之间的联系，通过数字疗法推动患者的参与和依从性，全球已有超过440万人使用过Glooko平台。

By seamlessly integrating with electronic health records (EHRs), providing a unified device ecosystem, and delivering actionable insights, Glooko aims to enhance clinical workflows and improve outcomes for people with diabetes and their care providers. For more information, please visit .

通过与电子健康记录 (EHR) 无缝集成、提供统一的设备生态系统以及提供可操作的见解，Glooko 致力于优化临床工作流程，并改善糖尿病患者及其护理人员的治疗效果。欲了解更多信息，请访问。

glooko.com

。

About Monarch Medical Technologies

关于Monarch Medical Technologies

Monarch Medical is the Charlotte, NC-based maker of the EndoTool Glucose Management System, a leading enterprise solution for inpatient glycemic control. Founded by clinicians, Monarch’s mission is to improve patient safety and outcomes through precise insulin dosing technology. The EndoTool platform has been adopted by hospitals and health systems across the United States to standardize and optimize insulin therapy, virtually eliminating severe hypoglycemia and reducing hyperglycemia in critical care settings.

Monarch Medical 是位于北卡罗来纳州夏洛特的公司，旗下产品 EndoTool 血糖管理系统是用于住院患者血糖控制的领先企业解决方案。Monarch 由临床医生创立，其使命是通过精确的胰岛素剂量技术提高患者的安全性和治疗效果。EndoTool 平台已被美国各地的医院和卫生系统采用，以标准化和优化胰岛素治疗，几乎消除了严重低血糖，并减少了重症监护环境中的高血糖问题。

For more information, visit .

欲了解更多信息，请访问。

monarchmedtech.com

。

Originally announced September 23rd, 2025

最初发布于2025年9月23日